MedTrace Logo

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

NCT06514612 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2026-05-04

No results posted yet for this study

Summary

A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis

Conditions

  • Acquired Blepharophimosis

Interventions

DRUG

STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers

STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers

OTHER

Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers

Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers

Sponsors & Collaborators

  • Santen SAS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2026-08-01
Completion
2026-08-01

Countries

  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06514612 on ClinicalTrials.gov